Irinotecan Sucrosofate

Summary

Irinotecan Sucrosofate (CHEMBL5314381) is a phase-3 clinical-stage unknown; indicated across 5 conditions including exocrine pancreatic carcinoma and rectal cancer.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 10
• Chemistry: 3329.5 Da · C144H174N16O59S8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314381
Name	Irinotecan Sucrosofate
Type	Unknown
Max phase	3
FDA approved	no
PubChem CID	76964235
Molecular formula	C144H174N16O59S8
Molecular weight	3329.5
InChIKey	BCPSLKYBXGKPIW-RTXWKGGWSA-N

SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O

IUPAC name: tetrakis([(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate);[(2R,3R,4S,5R,6R)-2-[(2S,3S,4R,5R)-3,4-disulfooxy-2,5-bis(sulfooxymethyl)oxolan-2-yl]oxy-3,5-disulfooxy-6-(sulfooxymethyl)oxan-4-yl] hydrogen sulfate

Also known as: Irinotecan sucrosofate, MM-398, PEP-02, IRINOTECAN SUCROSOFATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
rectal cancer	2	MONDO:0006519	EFO:1000657
neoplasm	1	MONDO:0005070	EFO:0000616
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	3
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06958328	PHASE3	RECRUITING	Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06998940	PHASE3	RECRUITING	Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT01494506	PHASE3	COMPLETED	Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
NCT03337087	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
NCT06821997	PHASE2	RECRUITING	NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
NCT04753216	PHASE2	COMPLETED	Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01770353	PHASE1	COMPLETED	MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
NCT02231723	PHASE1	COMPLETED	A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
NCT02631733	PHASE1	COMPLETED	Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
NCT02640365	PHASE1	COMPLETED	A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).